On Friday, Piper Sandler reaffirmed its positive stance on Inspire Medical Systems (NYSE:NYSE:INSP), maintaining an Overweight rating with a $260.00 price target. The endorsement comes after a steep 14.15% decline in the company's share value over the past week, which the firm sees as a chance for investors to purchase at a lower price.
According to InvestingPro data, the company maintains a "GREAT" financial health score of 3.24, suggesting strong fundamentals despite recent market volatility. Piper Sandler's analysis followed a meeting with Inspire Medical (TASE:PMCN)'s management earlier this week, leading to several optimistic observations.
The firm highlighted Inspire Medical's solid performance in the fourth quarter, which was achieved despite some disruptions caused by hurricanes. With impressive revenue growth of 32.52% and an industry-leading gross margin of 84.77% in the last twelve months, the company has demonstrated strong operational execution.
Analysts at Piper Sandler also addressed concerns about the company's second-half guidance for 2025, suggesting that worries are exaggerated and the guidance may be on the conservative side. They anticipate that profit and loss leverage will continue into approximately 2025, propelled by improvements in gross margins and reductions in selling, general, and administrative expenses.
The company's fifth-generation product, which has begun a soft launch, is expected to gain momentum as a full launch is targeted for the second half of 2025. This new generation device is notable for the removal of the pressure sensor lead, which is expected to shorten procedure times, increase throughput at medical centers, simplify the procedure for ear, nose, and throat (ENT) surgeons, and reduce adverse event rates.
Piper Sandler's report also addressed investor concerns regarding physician reimbursement for the new generation device, suggesting these concerns have contributed to the stock's underperformance since Monday. However, the firm views the recent downturn as an overreaction and recommends reiterating an Overweight rating with a $260 price target, seeing the pullback as an opportunity for investors to buy into Inspire Medical Systems at a more attractive price point.
InvestingPro analysis suggests the stock is currently slightly undervalued, with 11 additional exclusive ProTips and a comprehensive Pro Research Report available for subscribers seeking deeper insights into this medical technology leader.
In other recent news, Inspire Medical Systems exceeded analysts' expectations with its fourth quarter 2024 revenue, estimated between $239.5 million and $239.7 million, surpassing the consensus estimate of $232 million.
The company's full-year 2025 revenue guidance aligns closely with the consensus of $950.7 million. Inspire Medical's fourth quarter revenue indicates a 25% increase compared to the same quarter of the previous year. The company also reported the activation of 72 new centers in the U.S. and the creation of 12 new sales territories during the fourth quarter.
Moreover, Inspire Medical announced a soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S. The company also implemented a new organizational structure, including the appointment of Jason Kelly as the new Chief Manufacturing and Quality Officer. Piper Sandler analysts projected that Inspire Medical would outperform Q4 expectations and set comfortable 2025 guidance.
RBC Capital Markets also provided a favorable outlook for the Medical Supplies & Devices sector for 2025, highlighting Inspire Medical as a dominant player in treating obstructive sleep apnea.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.